Newspaper Publication inrespect of Unaudited Financials for the Q ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has published its unaudited standalone financial results for the quarter ended 31 December 2025 in the Navprabha and Navhind Times newspapers, as required under SEBI LODR regulations. Total income from operations for Q3 FY26 stood at ₹1,877.46 lakhs, marginally up from ₹1,839.74 lakhs in Q3 FY25 (about 2% YoY growth). Net profit after tax jumped to ₹97.51 lakhs in Q3 FY26 from ₹55.55 lakhs in Q3 FY25, a strong ~76% YoY increase, and also rose sharply from ₹52.43 lakhs in the previous quarter (Q2 FY26). EPS for the quarter came in at ₹1.01 versus ₹0.57 in Q3 FY25. The results were approved by the Board on 6 February 2026. The filing also includes a notice about SEBI's special window (5 Feb 2026 to 4 Feb 2027) for transfer and dematerialisation of physical securities.
Strong quarterly profit growth, both year-on-year and sequentially, is a positive signal for shareholders, though the modest top-line growth suggests margin expansion drove the earnings beat. The stock may see mild positive sentiment, but the small-cap scale limits broader market impact.